Jazz Pharmaceuticals (JAZZ) Total Liabilities (2010 - 2026)

Jazz Pharmaceuticals' Total Liabilities history runs 17 years deep, the most recent figure standing at $11.9 billion for Q1 2026.

• On a quarterly basis, Total Liabilities rose 2.82% year-over-year to $11.9 billion in Q1 2026; TTM through Mar 2026 was $11.9 billion, a 2.82% increase from a year earlier, with the FY2025 full-year figure at $11.7 billion, down 2.94% from the prior year.
• Total Liabilities improved to $11.9 billion in Q1 2026 per JAZZ's latest filing, from $11.7 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $12.3 billion in Q3 2024 and bottomed at $10.4 billion in Q3 2022.
• The 5-year median for Total Liabilities is $11.4 billion (2025), against an average of $11.4 billion.
• Biggest YoY gain for Total Liabilities was 74.19% in 2022; the steepest drop was 16.78% in 2022.
• Year by year, Total Liabilities stood at $10.8 billion in 2022, then increased by 5.15% to $11.4 billion in 2023, then advanced by 5.43% to $12.0 billion in 2024, then fell by 2.94% to $11.7 billion in 2025, then grew by 1.72% to $11.9 billion in 2026.
• Per Business Quant, the three latest JAZZ Total Liabilities figures stand at $11.9 billion (Q1 2026), $11.7 billion (Q4 2025), and $11.4 billion (Q3 2025).